BACKGROUND	A randomized trial of vinorelbine plus gemcitabine followed by docetaxel ( VGD ) versus paclitaxel plus carboplatin ( PC ) in patients with advanced non-small-cell lung cancer showed no difference in overall survival ( median survival time : 13.6 versus 14.1 months ) between the two treatment groups .\